Diversifying Business Risk through a Combination of the Prescription Pharmaceutical and Healthcare Businesses
First written in FY2017. 7 of 15 entries say "Restated". Latest entry: FY2026.
KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2022, 2 years before the typical company in this theme (2024).
12 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「Under Vision 110 –Stage1– (fiscal 2023 to fiscal 2025), the first stage, the company set "Transforming the business structure to realise Vision 110" as its statement and is pursuing business strategies for the new pharmaceutical business, including strengthening its ability to create high-value new drugs addressing medical needs, expanding its development pipeline through in-licensing, and maximising the proportion of new drugs」
The company has shifted from its previous direction of developing a diversified portfolio to describing Stage1's results as a transformation of the business structure centred on the new pharmaceutical business's capabilities to create and in-license drugs and increase the proportion of new drugs. - FY2024RestatedAnnual report
「The company aims to become a company that places at its core a new pharmaceutical business that continuously provides high-value new drugs addressing medical needs, develops health-related businesses in combination, and contributes broadly to people's health.」
The company continues to pursue the target state of Vision 110, which places the new pharmaceutical business at its core and develops health-related businesses in combination. - FY2024-Q3RestatedAnnual report
「In the fiscal year marking the Group’s 100th anniversary, we launched the newly formulated long-term vision, “Vision 110 (FY2023–FY2032),” and medium-term management plan, “Vision 110—Stage 1—(FY2023–FY2025).”」
The company continues, alongside Stage1, to pursue Vision 110's business concept of placing the new pharmaceutical business at its core and developing health-related businesses in combination. - FY2024-Q2RestatedAnnual report
「Based on the long-term vision Vision 110, the company has set as its target state a company that places at its core a new pharmaceutical business that continuously provides high-value new drugs addressing medical needs, develops health-related businesses in combination, and contributes broadly to people's health.」
The company has reaffirmed the target state of Vision 110, which places the new pharmaceutical business at its core and develops health-related businesses in combination. - FY2023ReframedAnnual report
「The company will make its new drug business the core of group management and vigorously drive the business forward, while developing its generic drug, infection-related and contract pharmaceutical manufacturing businesses in combination, with the aim of achieving further growth over the next 100 years.」
The company has established a structure with the new drug business at its core and operations spanning 4 areas: generics, infection-related products and services, and contract pharmaceutical manufacturing. - FY2023-Q2ReframedAnnual report
「Through this restructuring, the group will make its new drug business the core of group management and vigorously drive the business forward, while developing its generic drug, infection-related and contract pharmaceutical manufacturing businesses in combination, with the aim of achieving further growth over the next 100 years.」
The company has organised its diversified business model around 4 areas, with the new drug business at its core: generic drugs, infection-related products and services, and contract pharmaceutical manufacturing. - FY2021-Q3RestatedAnnual report
「Beginning this fiscal year, under the new medium-term management plan “HOPE100-Stage 3- (FY2020-FY2023),” the group is consolidating its healthcare business in areas centred on infectious diseases and promoting its integration with the prescription pharmaceutical business.」
The company continues to concentrate its healthcare business on infection-related areas and combine it with its prescription pharmaceutical business. - FY2021-Q2RestatedAnnual report
「Beginning this fiscal year, under the new medium-term management plan “HOPE100-Stage 3- (FY2020-FY2023),” the group is consolidating its healthcare business in areas centred on infectious diseases and promoting its integration with the prescription pharmaceutical business.」
The company continues to pursue the combination of its new drug, generic drug and infection-related businesses by concentrating on infection-related areas and combining them with its prescription pharmaceutical business. - FY2021-Q1ReframedAnnual report
「Beginning this fiscal year, under the new medium-term management plan “HOPE100-Stage 3- (FY2020-FY2023),” the group is consolidating its healthcare business in areas centred on infectious diseases and promoting its integration with the prescription pharmaceutical business.」
The company has moved from its previous model of diversifying risk through a combination of prescription pharmaceuticals and healthcare to a model combining infection-related areas, centred on infectious diseases, with its prescription pharmaceutical business. - FY2020ReframedAnnual report
「To become a company recognised worldwide for creating innovative new drugs, the company will combine and develop its new drug, generic drug and infection-related businesses, covering the prevention, diagnosis and treatment of infectious diseases, to support people's health across a broad range of areas.」
The company has moved from its previous model of diversifying risk through a combination of prescription pharmaceuticals and healthcare to a model combining and developing 3 businesses: new drugs, generics and infection-related products and services covering prevention, diagnosis and treatment. - FY2019RestatedAnnual report
「We aim to evolve into a “company supporting healthy lifestyles” that combines the prescription pharmaceutical and healthcare businesses, diversifies business risk and grows soundly and sustainably.」
The company has reaffirmed its direction of diversifying risk through a combination of its 2 businesses and evolving into a company that supports healthy living. - FY2018RestatedAnnual report
「We aim to evolve into a “company supporting healthy lifestyles” that combines the prescription pharmaceutical and healthcare businesses, diversifies business risk and grows soundly and sustainably.」
The company has reaffirmed its direction of diversifying risk and achieving sustainable growth by combining its prescription pharmaceutical and healthcare businesses. - FY2017First statedAnnual report
「We aim to evolve into a “company supporting healthy lifestyles” that combines the prescription pharmaceutical and healthcare businesses, diversifies business risk and grows soundly and sustainably.」
The Group intends to diversify business risk by combining the 2 businesses and evolve into a company supporting healthy lifestyles.